Breaking News Instant updates and real-time market news.

CVS

CVS Health

$53.84

1.025 (1.94%)

, INFY

Infosys

$10.53

-0.025 (-0.24%)

10:19
04/15/19
04/15
10:19
04/15/19
10:19

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CVS Health (CVS) downgraded to Perform from Outperform at Oppenheimer with analyst Michael Wiederhorn saying he views it as more of a long-term opportunity given the potential timeline to execute on its strategy and the near-term legacy business challenges. 2. Infosys (INFY) downgraded to Hold from Buy at Deutsche Bank and Investec, to Reduce from Neutral at Nomura Instinet, to Underperform from Neutral at Credit Suisse, to Equal Weight from Overweight at Morgan Stanley, and to Neutral from Buy at Citi and BofA/Merrill. 3. Celanese (CE) downgraded to Hold from Buy at Deutsche Bank with analyst David Begleiter saying the company's leadership transition creates uncertainty. 4. Alliance Data (ADS) downgraded to Underweight from Equal Weight at Stephens and to Market Perform from Outperform at BMO Capital. 5. Wells Fargo (WFC) downgraded to Neutral from Conviction Buy at Goldman Sachs, to In Line from Outperform at Evercore ISI, and to Neutral from Buy at BofA/Merrill and Buckingham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

CVS

CVS Health

$53.84

1.025 (1.94%)

INFY

Infosys

$10.53

-0.025 (-0.24%)

CE

Celanese

$104.67

-0.6 (-0.57%)

ADS

Alliance Data

$165.00

-15.89 (-8.78%)

WFC

Wells Fargo

$46.69

0.2 (0.43%)

  • 15

    Apr

  • 18

    Apr

  • 23

    Apr

  • 23

    Apr

  • 25

    Apr

  • 01

    May

  • 29

    May

  • 05

    Jun

  • 13

    Jul

  • 16

    Jul

  • 12

    Oct

  • 13

    Nov

CVS CVS Health
$53.84

1.025 (1.94%)

04/15/19
04/15/19
DOWNGRADE

Perform
CVS Health downgraded to Perform at Oppenheimer
As previously reported, Oppenheimer analyst Michael Wiederhorn downgraded CVS Health to Perform from Outperform saying that he is looking to reset the bar on his rating, as he views it as more of a long-term opportunity given the potential timeline to execute on its strategy and the near-term legacy business challenges. Furthermore, the analyst expects the drug-price noise out of Washington to continue for the foreseeable future. Lastly, Wiederhorn notes that he remains bullish on the overall managed care sector, but CVS's exposure to the business is still quite modest, and he would prefer other names in the space right now.
04/15/19
OPCO
04/15/19
DOWNGRADE
OPCO
Perform
CVS Health downgraded to Perform from Outperform at Oppenheimer
04/11/19
04/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with a Hold at HSBC. 2. Apple (AAPL), Dell Technologies (DELL), and HP Inc. (HPQ) initiated with a Neutral at Credit Suisse. 3. Yeti (YETI) initiated with an Outperform at Cowen. 4. CVS Health (CVS) initiated with a Market Perform at BMO Capital. 5. Canadian Solar (CSIQ) assumed with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/19
BMOC
04/10/19
INITIATION
BMOC
Market Perform
CVS Health initiated with a Market Perform at BMO Capital
BMO Capital analyst Matt Borsch initiated CVS Health with a Market Perform rating and a $58 price target. The analyst said that he is aware of the low valuation of the stock, but is "wary of further deterioration in the outlook given headwinds on CVS legacy businesses that have recently intensified," and is not confident "the pressures will diminish next year."
INFY Infosys
$10.53

-0.025 (-0.24%)

04/15/19
DBAB
04/15/19
DOWNGRADE
DBAB
Hold
Infosys downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Srinivas Roa downgraded Infosys to Hold from Buy citing "soft" margins following the company's Q4 results and fiscal 2020 outlook.
04/15/19
NOMU
04/15/19
DOWNGRADE
NOMU
Reduce
Infosys downgraded to Reduce from Neutral at Nomura Instinet
Nomura Instinet analyst Rishit Parikh downgraded Infosys to Reduce from Neutral with a price target of 680 rupees. The analyst sees a weaker growth outlook and slower earnings growth following Friday's Q4 results and fiscal 2020 outlook.
04/15/19
INVC
04/15/19
DOWNGRADE
INVC
Hold
Infosys downgraded to Hold from Buy at Investec
04/15/19
FBCO
04/15/19
DOWNGRADE
FBCO
Underperform
Infosys downgraded to Underperform from Neutral at Credit Suisse
CE Celanese
$104.67

-0.6 (-0.57%)

04/14/19
DBAB
04/14/19
DOWNGRADE
DBAB
Hold
Celanese downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst David Begleiter downgraded Celanese to Hold from Buy.
02/06/19
02/06/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PayPal (PYPL) downgraded to Neutral from Buy at Guggenheim with the firm citing balanced risk/reward. 2. Arlo Technologies (ARLO) downgraded to Underperform from Neutral at BofA/Merrill and to Market Perform from Outperform at Cowen. 3. Celanese (CE) downgraded to Market Perform from Outperform at Cowen with analyst Charles Neivert saying recent subtle changes in industry fundamentals and the macro outlook have made him more cautious. 4. Estee Lauder (EL) downgraded to Hold from Buy at Berenberg with analyst Rosie Edwards saying that while the company's Q2 results were "strong across the board," she expects top-line growth to moderate, due mainly to skincare and Asia-Pacific. 5. Vanda Pharmaceuticals (VNDA) downgraded to Neutral from Overweight at Cantor Fitzgerald with analyst Charles Duncan saying the company's complaint against the FDA reduces visibility on development timelines for tradipitant in gastroparesis, perhaps even pruritus, and may also affect Hetlioz label expansion efforts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/06/19
COWN
02/06/19
DOWNGRADE
Target $108
COWN
Market Perform
Cowen says headwinds leave little upside, downgrades Celanese to Market Perform
As reported previously, Cowen analyst Charles Neivert downgraded Celanese to Market Perform from Outperform. The analyst said recent subtle changes in industry fundamentals and the macro outlook have made him more cautious. He believes margin pressure will be present throughout most of 2019 based on headwinds from feedstocks, capacity, and a weakening macro versus consensus. Neivert lowered his price target to $108 from $122 on Celanese shares.
04/15/19
DBAB
04/15/19
DOWNGRADE
Target $110
DBAB
Hold
Deutsche downgrades Celanese to Hold on leadership uncertainty
Deutsche Bank analyst David Begleiter yesterday downgraded Celanese to Hold from Buy with an unchanged price target of $110. The company's leadership transition creates uncertainty, Begleiter tells investors in a research note. The analyst, who's had a Buy rating on the shares for 14 years, believes the management change will inhibit new buyers in the stock.
ADS Alliance Data
$165.00

-15.89 (-8.78%)

04/15/19
WELS
04/15/19
NO CHANGE
Target $200
WELS
Outperform
Wells Fargo views Alliance Data sale of Epsilon to Publicis as positive
Wells Fargo analyst Timothy Willi notes that Alliance Data (ADS) announced an agreement to sell Epsilon to Publicis (PUBGY) for $4.4B in cash, in a deal that is expected to close in early Q3. The analyst ultimately views this development as a positive, given the accretive nature of the transaction and the stream-lining of Alliance Data's business, which will be better-received by investors. Willi expects further detail on the company's Q1 earnings call, and believes management may look to further refine the business through a sale of LoyaltyOne following the Epsilon sale. The analyst reiterates an Outperform rating and $200 price target on Alliance Data's shares.
04/15/19
SPHN
04/15/19
DOWNGRADE
Target $165
SPHN
Underweight
Alliance Data downgraded to Underweight from Equal Weight at Stephens
Stephens analyst Vincent Caintic downgraded Alliance Data to Underweight and lowered his price target to $165 from $188. The analyst believes that the $4.4B sale price for Epsilon and the $3.5B net proceeds to the company was "lower than market expectations". Caintic adds that even though it is "tough to be negative" on Alliance Data ahead of his anticipated big buyback, he sees no positive catalysts for the stock in 2019 at this time.
04/15/19
KEYB
04/15/19
NO CHANGE
KEYB
Sector Weight
Alliance Data sale of Epsilon could unlock shareholder value, says KeyBanc
KeyBanc analyst Josh Beck applauds strategic efforts at Alliance Data (ADS) and views the $4.4B sale of the Epsilon marketing business to Publicis (PUBGY) as an unlock of shareholder value provided the 10-times EBITDA multiple. However, the analyst believes the transition within the card business to re-orient towards verticals such as home, children, and beauty remains a work-in-progress. Beck expects in-line results and guidance ex-Epsilon and remains Sector Weight as he looks for better visibility into the evolution of the card business and credit trends.
04/15/19
WEDB
04/15/19
NO CHANGE
Target $180
WEDB
Neutral
Alliance Data structural challenges remain despite Epsilon sale, says Wedbush
Wedbush analyst Moshe Katri reiterates a Neutral rating and a $180 price target for Alliance Data (ADS) despite reported Epsilon's sale to Publicis (PUBGY) for $4.4B in cash. On one hand, his estimated Alliance Data stand-alone pro forma model suggests such a transaction could be highly accretive for its CEPS given Epsilon's lackluster growth rates combined with an inflated cost structure. On the other hand, the analyst notes that results from Alliance Data's 100-plus retailers will likely continue to be cannibalized by the "Amazon" (AMZN) effect, capping transaction volume growth and impacting results of the company's largest segment. Furthermore, the company will be selling its "big data"/analytics business, which in the past, has been viewed as a significant competitive differentiator, he adds.
WFC Wells Fargo
$46.69

0.2 (0.43%)

04/15/19
EVER
04/15/19
DOWNGRADE
EVER
In Line
Wells Fargo downgraded to In Line from Outperform at Evercore ISI
04/15/19
GSCO
04/15/19
DOWNGRADE
Target $48
GSCO
Neutral
Goldman downgrades Wells Fargo to Neutral, takes off Conviction list
Goldman Sachs analyst Richard Ramsden on Friday night downgraded Wells Fargo to Neutral from Buy and removed the shares from his firm's Americas Conviction List. The recent departure of Tim Sloan and questions over the time it will take to find a replacement, coupled with commentary on the Q1 earnings call around weaker than expected net interest income growth for 2019, has increased focus on Wells Fargo's ability to meet near term and longer term financial targets, Ramsden tells investors in a research note. The analyst expects the company's medium term operating leverage potential to be impacted by weaker net interest income growth. He cut his price target for the shares to $48 from $58.
04/15/19
DBAB
04/15/19
NO CHANGE
Target $48
DBAB
Hold
Wells Fargo price target lowered to $48 from $54 at Deutsche Bank
Deutsche Bank analyst Matt O'Connor lowered his price target for Wells Fargo to $48 from $54 citing management's reduced outlook for net interest income and fewer share buybacks. The analyst keeps a Hold rating on Wells Fargo.
04/15/19
04/15/19
DOWNGRADE

Neutral
Wells Fargo downgraded to Neutral at BofA/Merrill
As previously reported, BofA/Merrill downgraded Wells Fargo to Neutral from Buy and cut its price target to $50 from $57. Analyst Erika Najarian said there is a further deterioration in earning visibility and shares lack an upside catalysts until a new CEO is announced.

TODAY'S FREE FLY STORIES

F

Ford

$9.41

-0.17 (-1.77%)

17:53
04/25/19
04/25
17:53
04/25/19
17:53
Hot Stocks
Ford CFO: Encouraged by progress made in China toward return to profitability »

Sees FY19 revenue growth,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

CIR

Circor

$34.53

-2 (-5.48%)

17:48
04/25/19
04/25
17:48
04/25/19
17:48
Earnings
Circor sees Q2 adjusted EPS 40c-48c, consensus 54c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

F

Ford

$9.41

-0.17 (-1.77%)

17:48
04/25/19
04/25
17:48
04/25/19
17:48
Hot Stocks
Ford CFO says Q1 market share declined to 5.9% from 6.5% »

Says EBIT and EBIT margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

CIR

Circor

$34.53

-2 (-5.48%)

17:46
04/25/19
04/25
17:46
04/25/19
17:46
Earnings
Circor reports Q1 adjusted EPS 38c, consensus 37c »

Reports Q1 revenue $270M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 09

    May

F

Ford

$9.41

-0.17 (-1.77%)

17:45
04/25/19
04/25
17:45
04/25/19
17:45
Hot Stocks
Breaking Hot Stocks news story on Ford »

Ford sees over $1B in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

ARGO

Argo Group

$74.21

-0.245 (-0.33%)

17:43
04/25/19
04/25
17:43
04/25/19
17:43
Upgrade
Argo Group rating change at William Blair »

Argo Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 11

    Jun

ILMN

Illumina

$318.91

4.47 (1.42%)

17:36
04/25/19
04/25
17:36
04/25/19
17:36
Earnings
Illumina raises FY19 adj. EPS view to $6.63-$6.73 from $6.50-$6.60 »

Consensus $6.53. Backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 31

    May

  • 06

    Aug

  • 03

    Sep

HTH

Hilltop Holdings

$19.90

-0.19 (-0.95%)

17:35
04/25/19
04/25
17:35
04/25/19
17:35
Earnings
Hilltop Holdings reports Q1 EPS 41c, consensus 26c »

Hilltop's annualized…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

F

Ford

$9.41

-0.17 (-1.77%)

17:35
04/25/19
04/25
17:35
04/25/19
17:35
Hot Stocks
Ford backs long-term revenue growth target view exceeding global GDP »

Backs FY19 long-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 24

    Jul

  • 23

    Oct

ILMN

Illumina

$318.91

4.47 (1.42%)

17:32
04/25/19
04/25
17:32
04/25/19
17:32
Earnings
Illumina reports Q1 adj. EPS $1.60, consensus $1.34 »

Reports Q1 revenue $846M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

  • 31

    May

  • 06

    Aug

  • 03

    Sep

GIB

CGI Group

$71.16

0.36 (0.51%)

17:30
04/25/19
04/25
17:30
04/25/19
17:30
Downgrade
CGI Group rating change at CIBC »

CGI Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

ARGO

Argo Group

$74.21

-0.245 (-0.33%)

17:30
04/25/19
04/25
17:30
04/25/19
17:30
Upgrade
Argo Group rating change at William Blair »

Argo Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 11

    Jun

SBUX

Starbucks

$77.07

0.65 (0.85%)

, NSRGY

Nestle

$0.00

(0.00%)

17:30
04/25/19
04/25
17:30
04/25/19
17:30
Hot Stocks
Starbucks sees FY19 adjusted effective tax rate 19%-21% »

Says Nestle alliance…

SBUX

Starbucks

$77.07

0.65 (0.85%)

NSRGY

Nestle

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 07

    May

GCI

Gannett

$9.26

-0.11 (-1.17%)

17:29
04/25/19
04/25
17:29
04/25/19
17:29
Hot Stocks
Gannett still urges holders to vote 'FOR ALL' of its director nominees »

Gannett issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 16

    May

PRA

ProAssurance

$36.08

0.08 (0.22%)

17:28
04/25/19
04/25
17:28
04/25/19
17:28
Hot Stocks
ProAssurance concerned over loss trends in healthcare professional liability »

"Our concern about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 22

    May

  • 22

    May

NCR

NCR Corp.

$28.62

-0.755 (-2.57%)

17:27
04/25/19
04/25
17:27
04/25/19
17:27
Syndicate
NCR Corp. files to sell 20.39M shares of common stock »

Also files to sell up to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

PRA

ProAssurance

$36.08

0.08 (0.22%)

17:24
04/25/19
04/25
17:24
04/25/19
17:24
Earnings
ProAssurance reports Q1 EPS 8c, consensus 35c »

Reports Q1 revenue $269M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 22

    May

  • 22

    May

MRK

Merck

$76.33

1.6 (2.14%)

17:22
04/25/19
04/25
17:22
04/25/19
17:22
Hot Stocks
Merck provides update on Phase 3 KEYNOTE-062 trial »

Merck announced topline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 03

    May

  • 04

    May

  • 06

    May

  • 18

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 16

    Jul

  • 06

    Aug

  • 20

    Sep

ACB

Aurora Cannabis

$9.07

-0.045 (-0.49%)

, CGC

Canopy Growth

$48.20

-0.13 (-0.27%)

17:22
04/25/19
04/25
17:22
04/25/19
17:22
Initiation
Aurora Cannabis, Canopy Growth, HEXO Corp, Constellation Brands, AB InBev, Altria Group, Walgreens Boots Alliance, CVS Health, Rite Aid initiated  »

Desjardins initiates HEXO…

ACB

Aurora Cannabis

$9.07

-0.045 (-0.49%)

CGC

Canopy Growth

$48.20

-0.13 (-0.27%)

HEXO

HEXO Corp

$7.14

0.01 (0.14%)

STZ

Constellation Brands

$212.19

2.12 (1.01%)

BUD

AB InBev

$86.63

-1.57 (-1.78%)

MO

Altria Group

$51.42

-3.28 (-6.00%)

WBA

Walgreens Boots Alliance

$52.67

-0.8 (-1.50%)

CVS

CVS Health

$53.24

0.31 (0.59%)

RAD

Rite Aid

$8.98

-0.64 (-6.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 07

    May

  • 16

    May

  • 16

    May

  • 19

    May

  • 18

    Jun

DRQ

Dril-Quip

$43.59

-0.87 (-1.96%)

17:21
04/25/19
04/25
17:21
04/25/19
17:21
Earnings
Dril-Quip sees Q2 revenue at high end of $90M-$100M, consensus $95M »

Raises Q2 expectations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

SBUX

Starbucks

$77.07

0.65 (0.85%)

17:20
04/25/19
04/25
17:20
04/25/19
17:20
Hot Stocks
Starbucks says on track to deliver on capital return commitment »

Says on track to deliver…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

DRQ

Dril-Quip

$43.59

-0.87 (-1.96%)

17:20
04/25/19
04/25
17:20
04/25/19
17:20
Earnings
Dril-Quip reports Q1 EPS (17c), consensus (6c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

SBUX

Starbucks

$77.07

0.65 (0.85%)

17:17
04/25/19
04/25
17:17
04/25/19
17:17
Hot Stocks
Starbucks says 'well-positioned' for long-term growth in China »

Sees 6,000 China stores…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SBUX

Starbucks

$77.07

0.65 (0.85%)

17:13
04/25/19
04/25
17:13
04/25/19
17:13
Hot Stocks
Starbucks says will have Nitro Cold Brew in all U.S. stores by end of FY19 »

Says EMEA region nearly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LMT

Lockheed Martin

$328.97

-1.15 (-0.35%)

17:13
04/25/19
04/25
17:13
04/25/19
17:13
Hot Stocks
Lockheed Martin awarded $723.55M Army contract modification »

Lockheed Martinhas been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 28

    Apr

  • 29

    May

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.